Antonia Digklia1, Ioannis A Voutsadakis1. 1. Antonia Digklia, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland.
Abstract
AIM: To discuss treatment with eribulin in clinical practice outside a clinical trial. METHODS: Archives of patients treated for metastatic breast cancer were reviewed and 21 patients treated with the new chemotherapeutic eribulin mesylate, a synthetic analog of a natural marine product, were identified. Information on patients' characteristics and treatment outcomes was extracted. Treatment with eribulin mesylate was initiated at the recommended dose of 1.4 mg/m(2) on days 1 and 8 of a 21-day cycle in 17 patients and at a decreased dose of 1.1 mg/m(2) on days 1 and 8 of a 21-day cycle in 4 patients due to comorbidities and frailty. Efficacy of the drug was evaluated using the revised Response Evaluation Criteria in Solid Tumors criteria. Progression-Free Survival and overall survival (OS) were calculated using the Kaplan-Meier method starting from the date of eribulin therapy initiation to the date of disease progression documentation or death, respectively. RESULTS: The median age of patients at the time of eribulin mesylate treatment was 53 years (range 34-75). Sixteen patients had estrogen receptor (ER) and/or partial response (PR) positive disease and 5 had ER/PR negative disease (all triple negative). Eight patients had received 2 or 3 previous lines of chemotherapy for metastatic disease and 13 patients had received 4 or more lines of treatment. The median number of cycles of eribulin received was 3 (range 1-16 years). All patients, except one, discontinued treatment due to progressive disease and one patient due to adverse effects. Six patients had a dose reduction due to side effects. All patients had progressed at the time of the report with a median time to progression of 3 mo (range 1 to 14 mo). Fifteen patients had died with a median OS of 7 mo (range 1-18 mo). Six patients were alive with a median follow-up of 13.5 mo (range 7 to 19 mo). CONCLUSION: This series of patients confirms the activity of eribulin in a heavily pre-treated metastatic breast cancer population consistent with phase II and III trials.
AIM: To discuss treatment with eribulin in clinical practice outside a clinical trial. METHODS: Archives of patients treated for metastatic breast cancer were reviewed and 21 patients treated with the new chemotherapeutic eribulin mesylate, a synthetic analog of a natural marine product, were identified. Information on patients' characteristics and treatment outcomes was extracted. Treatment with eribulin mesylate was initiated at the recommended dose of 1.4 mg/m(2) on days 1 and 8 of a 21-day cycle in 17 patients and at a decreased dose of 1.1 mg/m(2) on days 1 and 8 of a 21-day cycle in 4 patients due to comorbidities and frailty. Efficacy of the drug was evaluated using the revised Response Evaluation Criteria in Solid Tumors criteria. Progression-Free Survival and overall survival (OS) were calculated using the Kaplan-Meier method starting from the date of eribulin therapy initiation to the date of disease progression documentation or death, respectively. RESULTS: The median age of patients at the time of eribulin mesylate treatment was 53 years (range 34-75). Sixteen patients had estrogen receptor (ER) and/or partial response (PR) positive disease and 5 had ER/PR negative disease (all triple negative). Eight patients had received 2 or 3 previous lines of chemotherapy for metastatic disease and 13 patients had received 4 or more lines of treatment. The median number of cycles of eribulin received was 3 (range 1-16 years). All patients, except one, discontinued treatment due to progressive disease and one patient due to adverse effects. Six patients had a dose reduction due to side effects. All patients had progressed at the time of the report with a median time to progression of 3 mo (range 1 to 14 mo). Fifteen patients had died with a median OS of 7 mo (range 1-18 mo). Six patients were alive with a median follow-up of 13.5 mo (range 7 to 19 mo). CONCLUSION: This series of patients confirms the activity of eribulin in a heavily pre-treated metastatic breast cancer population consistent with phase II and III trials.
Entities:
Keywords:
Breast cancer; Case series; Eribulin; Metastatic; Retrospective; Treatment
Authors: Elias Pean; Sigrid Klaar; Eva Gil Berglund; Tomas Salmonson; Jeanett Borregaard; Kenneth F Hofland; Jens Ersbøll; Eric Abadie; Rosa Giuliani; Francesco Pignatti Journal: Clin Cancer Res Date: 2012-07-24 Impact factor: 12.531
Authors: Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves Journal: Lancet Date: 2011-03-02 Impact factor: 79.321
Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Antoinette R Tan; Eric H Rubin; Diana C Walton; Dale E Shuster; Y Nancy Wong; Fang Fang; Simon Ashworth; Lee S Rosen Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531
Authors: Teresa Gamucci; Andrea Michelotti; Laura Pizzuti; Lucia Mentuccia; Elisabetta Landucci; Isabella Sperduti; Luigi Di Lauro; Alessandra Fabi; Giuseppe Tonini; Valentina Sini; Nello Salesi; Ilaria Ferrarini; Angela Vaccaro; Ida Pavese; Enzo Veltri; Luca Moscetti; Paolo Marchetti; Patrizia Vici Journal: J Cancer Date: 2014-03-20 Impact factor: 4.207
Authors: Kristi McIntyre; Joyce O'Shaughnessy; Lee Schwartzberg; Stefan Glück; Erhan Berrak; James X Song; David Cox; Linda T Vahdat Journal: Breast Cancer Res Treat Date: 2014-04-04 Impact factor: 4.872